Table 4.

Best overall response in Caucasian and Korean patients

Patients with response, n (%)	Caucasian patients									Korean patients			Total
	BI 836826 dose									BI 836826 dose
	1 mg	3 mg	9 mg	25 mg	50 mg	100 mg	150 mg	200 mg	Total	50 mg	100 mg	Total
	n = 1	n = 4	n = 3	n = 4	n = 6	n = 6	n = 6	n = 7	n = 37	n = 7	n = 4	n = 11	n = 48
ORR	0	0	0	0	0	2 (33.3)	0	0	2 (5.4)	1 (14.3)	0	1 (9.1)	3 (6.3)
CR	0	0	0	0	0	0	0	0	0	1 (14.3)	0	1 (9.1)	1 (2.1)
CRu	0	0	0	0	0	0	0	0	0	0	0	0	0
PR	0	0	0	0	0	2 (33.3)	0	0	2 (5.4)	0	0	0	2 (4.2)
SD	1 (100)	1 (25.0)	1 (33.3)	0	3 (50.0)	1 (16.7)	0	2 (28.6)	9 (24.3)	1 (14.3)	0	1 (9.1)	10 (20.8)
PD	0	2 (50)	2 (66.7)	4 (100.0)	2 (33.3)	2 (33.3)	5 (83.3)	4 (57.1)	21 (56.8)	5 (71.4)	4 (100.0)	9 (81.8)	30 (62.5)
NE	0	1 (25.0)	0	0	1 (16.7)	1 (16.7)	1 (16.7)	1 (14.3)	5 (13.5)	0	0	0	5 (10.4)

ORR overall response rate, CR complete remission, CRu complete remission unconfirmed, PR partial remission, SD stable disease, PD progressive disease, NE not evaluable